(B) (1) Every licensed health professional authorized to prescribe drugs shall keep a record of all controlled substances received and a record of all controlled substances administered, dispensed, or used other than by prescription. Every other person, except a pharmacist or a manufacturer, wholesaler, or other person licensed under section of the Revised Code, who is authorized to purchase and use controlled substances shall keep a record of all controlled substances purchased and used other than by prescription. The records shall be kept in accordance with division (C)(1) of this section.
Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women. 
Diarrhea is more common and sometimes more severe with flutamide than with other NSAAs.  In a comparative trial of combined androgen blockade for prostate cancer, the rate of diarrhea was 26% for flutamide and 12% for bicalutamide.  Moreover, 6% of flutamide-treated patients discontinued the drug due to diarrhea, whereas only % of bicalutamide-treated patients did so.  In the case of antiandrogen monotherapy for prostate cancer, the rates of diarrhea are 5–20% for flutamide, 2–5% for bicalutamide, and 2–4% for nilutamide .  In contrast to diarrhea, the rates of nausea and vomiting are similar among the three drugs.